ClinicalTrials.gg
RecruitingNCT07815119PEARL-LAACUpdated Sep 11, 2026

TEE-Guided Versus CCTA-Guided Preprocedural Imaging for Left Atrial Appendage Closure

An interventional study of Transesophageal Echocardiography-Guided Preprocedural Assessment and Cardiac Computed Tomography Angiography-Guided Preprocedural Assessment in Nonvalvular Atrial Fibrillation, sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Shanghai Zhongshan Hospital · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
590
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 376 studies in Atrial Fibrillation with a site in China — 161 open to participants now, 182 under way, 4 of them phase 3. Atrial Fibrillation · China.

Planned enrollment
65th of 255
590 · median 234
Started
2026
with 46 others
No phase
199 of 376
99 open now
Primary completion
2028-09
later than 148 of 181 live
Registered
368th of 376
by date

Among the 376 studies in Atrial Fibrillation with a site in China, this one is the 65th largest by planned enrollment of the 255 interventional ones that give a count, is one of 47 that started in 2026, is one of 199 with no phase, reaches primary completion later than 148 of the 181 other live ones, and was the 368th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

161 of the 376 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:

155 more — sign in →

All 161 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 376 studies in Atrial Fibrillation with a site in China, or all of them as a file.
02

Study summary

This prospective, open-label, multicenter randomized controlled trial will compare two preprocedural imaging assessment strategies in adults with nonvalvular atrial fibrillation who are scheduled to undergo percutaneous left atrial appendage closure (LAAC). Participants will be randomized 1:1 to a transesophageal echocardiography (TEE)-guided strategy or a cardiac computed tomography angiography (CCTA)-guided strategy for assessment of left atrial appendage anatomy and selection of the occluder type and size. LAAC and postprocedural management will otherwise follow routine clinical practice. The primary outcome is a composite of serious periprocedural safety events through 30 days. At 3 months (plus or minus 2 weeks), participants who undergo LAAC will receive both TEE and CCTA for blinded core-laboratory assessment of peridevice leak, device-related thrombus, and residual left atrial appendage patency. Clinical follow-up will continue through 12 months.

Read the detailed description

Eligible participants will be adults with nonvalvular atrial fibrillation for whom LAAC is planned for stroke prevention. After written informed consent and confirmation of eligibility, participants will be randomized in a 1:1 ratio through a centralized electronic system using center-stratified, variable-block randomization.

In the TEE-guided group, preprocedural planning will be based primarily on TEE measurements of left atrial appendage morphology, ostial dimensions, depth, and adjacent structures. In the CCTA-guided group, planning will be based primarily on CCTA assessment of morphology, three-dimensional anatomy, ostial area, depth, and adjacent structures. In both groups, the assigned modality will guide occluder type and size selection. Use of the nonassigned modality when clinically necessary will be documented. The indication for LAAC, the procedure itself, intraprocedural imaging, and postprocedural management will follow standardized routine care.

The trial has two linked components. The randomized strategy comparison evaluates procedural performance and early clinical safety. An embedded paired-imaging study will compare TEE and CCTA within the same participant at 3 months after LAAC. Clinical events will be adjudicated by an independent clinical event committee blinded to randomized assignment. Prespecified imaging outcomes will be assessed by a blinded imaging core laboratory. Follow-up visits are planned before discharge and at 3, 6, and 12 months after LAAC.

03

Conditions studied

  • Nonvalvular Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age 18 years or older. 2. Diagnosis of nonvalvular atrial fibrillation, including paroxysmal, persistent, or permanent atrial fibrillation.

    3. Planned percutaneous left atrial appendage closure for stroke prevention and considered by the investigator to meet an accepted indication for LAAC.

    4. Able to complete randomization and the assigned preprocedural imaging assessment.

    5. Expected to be able to complete paired TEE and CCTA follow-up at 3 months after LAAC.

    6. Able to complete protocol-specified clinical follow-up. 7. Written provided by the participant.

Exclusion criteria

Exclusion Criteria:

  • 1. Atrial fibrillation with moderate or severe mitral stenosis or a history of mechanical valve replacement.

    2. to TEE, such as severe esophageal disease or inability to tolerate the procedure.

    3. Contraindication to CCTA, such as severe renal dysfunction or a known allergy to iodinated contrast that cannot be adequately premedicated.

    4. Another established indication for long-term full-dose anticoagulation, such as a mechanical valve or active venous thromboembolism.

    5. shorter than 1 year or a severe noncardiovascular disease that may prevent completion of follow-up or reliable assessment of clinical events.

    6. Pregnancy or breastfeeding. 7. Any other condition that, in the investigator's judgment, makes participation inappropriate.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
590 participants (estimated)

Study arms

  • Active comparator
    TEE-Guided Preprocedural Imaging Assessment

    Before LAAC, left atrial appendage anatomy and procedural planning, including selection of occluder type and size, will be based primarily on transesophageal echocardiography. Use of the nonassigned modality is permitted when clinically necessary and will be recorded. LAAC and postprocedural care otherwise follow standardized routine practice.

    Diagnostic Test: Transesophageal Echocardiography-Guided Preprocedural Assessment

  • Experimental
    CCTA-Guided Preprocedural Imaging Assessment

    Before LAAC, left atrial appendage anatomy and procedural planning, including selection of occluder type and size, will be based primarily on cardiac computed tomography angiography. Use of the nonassigned modality is permitted when clinically necessary and will be recorded. LAAC and postprocedural care otherwise follow standardized routine practice.

    Diagnostic Test: Cardiac Computed Tomography Angiography-Guided Preprocedural Assessment

Interventions

  • Diagnostic testTransesophageal Echocardiography-Guided Preprocedural Assessment

    TEE is used as the primary preprocedural imaging modality to evaluate left atrial appendage morphology, ostial dimensions, depth, and relationships to adjacent structures and to guide occluder type and size selection.

  • Diagnostic testCardiac Computed Tomography Angiography-Guided Preprocedural Assessment

    CCTA is used as the primary preprocedural imaging modality to evaluate left atrial appendage morphology, three-dimensional anatomy, ostial area, depth, and relationships to adjacent structures and to guide occluder type and size selection.

06

What researchers measure

Primary outcomes

  1. Primary outcome: Composite incidence of periprocedural serious safety events

    Number and percentage of participants with at least one of the following events, adjudicated by a blinded independent clinical event committee: cardiovascular death; ischemic or hemorrhagic stroke; systemic embolism; clinically relevant pericardial effusion or cardiac tamponade; or another serious procedure-related complication. Prespecified serious procedure-related complications include device embolization, major vascular complications, acute kidney injury, or bleeding requiring transfusion, interventional treatment, or surgery.

    Time frame: From the start of the LAAC procedure through 30 days after the procedure

Secondary outcomes

  1. Secondary outcome 1: Proportion of participants with clinically relevant peridevice leak of at least 3 mm

    Maximum peridevice leak width will be measured separately by TEE and CCTA and adjudicated by the blinded imaging core laboratory. The proportion of participants with a maximum width of at least 3 mm will be reported for each modality and compared within participants.

    Time frame: 3 months after LAAC (allowed window: plus or minus 2 weeks)

  2. Secondary outcome 2: Proportion of procedures requiring replacement of the initially selected occluder

    Number and percentage of LAAC procedures in which the initially selected occluder is replaced because of inappropriate size, inability to achieve stable release, or another recorded procedural reason.

    Time frame: During the LAAC procedure

  3. Secondary outcome 3: Proportion of participants requiring crossover to the nonassigned preprocedural imaging strategy

    Number and percentage of participants for whom the nonassigned imaging modality is used as a principal basis for preprocedural planning after randomization. The reason for crossover will be recorded.

    Time frame: From randomization through completion of preprocedural planning

  4. Secondary outcome 4: Technical success of left atrial appendage closure

    Number and percentage of participants in whom the occluder is successfully released within the left atrial appendage, is not immediately removed, and is stable at completion of the procedure.

    Time frame: At completion of the LAAC procedure

  5. Secondary outcome 5: Incidence of individual components of the primary composite outcome

    Each component will be reported separately: cardiovascular death, ischemic stroke, hemorrhagic stroke, systemic embolism, clinically relevant pericardial effusion, cardiac tamponade, device embolization, major vascular complication, acute kidney injury, and bleeding requiring transfusion, interventional treatment, or surgery.

    Time frame: From the start of the LAAC procedure through 30 days after the procedure

  6. Secondary outcome 6: Proportion of participants with device-related thrombus

    Number and percentage of participants with device-related thrombus detected by TEE or CCTA and confirmed by the blinded imaging core laboratory.

    Time frame: 3 months after LAAC (allowed window: plus or minus 2 weeks)

  7. Secondary outcome 7: Proportion of participants with residual left atrial appendage patency

    Number and percentage of participants with residual left atrial appendage patency detected by TEE or CCTA and confirmed by the blinded imaging core laboratory.

    Time frame: 3 months after LAAC (allowed window: plus or minus 2 weeks)

  8. Secondary outcome 8: Paired agreement and disagreement between TEE and CCTA for key imaging abnormalities

    Within-participant comparison of TEE and CCTA for device-related thrombus, peridevice leak of at least 3 mm, and residual left atrial appendage patency. Discordant proportions will be compared using McNemar tests and agreement will be summarized using kappa statistics.

    Time frame: 3 months after LAAC (allowed window: plus or minus 2 weeks)

  9. Secondary outcome 9: Cumulative incidence of ischemic stroke

    Number and percentage of participants with an adjudicated ischemic stroke after LAAC.

    Time frame: From LAAC through 12 months; assessed at 3, 6, and 12 months

  10. Secondary outcome 10: Cumulative incidence of transient ischemic attack

    Number and percentage of participants with an adjudicated transient ischemic attack after LAAC.

    Time frame: From LAAC through 12 months; assessed at 3, 6, and 12 months

  11. Secondary outcome 11: Cumulative incidence of systemic embolism

    Number and percentage of participants with an adjudicated systemic embolic event after LAAC.

    Time frame: From LAAC through 12 months; assessed at 3, 6, and 12 months

  12. Secondary outcome 12: Cumulative incidence of major bleeding

    Number and percentage of participants with major bleeding defined as Bleeding Academic Research Consortium type 3 or higher.

    Time frame: From LAAC through 12 months; assessed at 3, 6, and 12 months

  13. Secondary outcome 13: Cumulative incidence of clinically relevant nonmajor bleeding

    Number and percentage of participants with clinically relevant nonmajor bleeding after LAAC.

    Time frame: From LAAC through 12 months; assessed at 3, 6, and 12 months

  14. Secondary outcome 14: All-cause mortality

    Number and percentage of participants who die from any cause after LAAC.From LAAC through 12 months; assessed at 3, 6, and 12 months

    Time frame: From LAAC through 12 months; assessed at 3, 6, and 12 months

  15. Secondary outcome 15: Cardiovascular mortality

    Number and percentage of participants who die from a cardiovascular cause after LAAC, as adjudicated by the independent clinical event committee.

    Time frame: From LAAC through 12 months; assessed at 3, 6, and 12 months

  16. Secondary outcome 16: Proportion of participants with modification of antithrombotic therapy

    Number and percentage of participants whose antithrombotic regimen, intensity, or planned duration is modified on the basis of follow-up imaging findings or clinical events. The reason for each modification will be recorded.

    Time frame: From discharge through 12 months after LAAC; assessed at 3, 6, and 12 months

07

Study locations

1 of 1 sites recruiting
  • Zhognshan Hospital ,Fudan University
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Deidentified individual participant data will not be shared because the currently approved informed consent permits coded study data to be used only within the scope of the present study and does not authorize use outside this study.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.

Of 794 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 24 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2026
First posted
Sep 11, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2029
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07815119
Responsible party
Sponsor
First posted
Sep 11, 2026
Start date
Sep 1, 2026
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Sep 11, 2026

Study contacts

Hao Jiang, MD
Contact
jiang.hao2@zs-hospital.sh.cn
+86-21-64041990 ext. 613397
Xiaochun Zhang, MD
Contact
zhang.xiaochun1@zs-hospital.sh.cn
+86-21-64041990 ext. 612846
Xiaochun Zhang
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion